Rol del PET/CT con 18FDG en patología no neoplásica / Role of 18FDG PET/CT in non-malignant diseases

La Tomografía por emisión de positrones/tomografía computada (PET/CT) se ha vuelto fundamental para la evaluación oncológica. En los últimos años se ha hecho evidente su utilidad para evaluar otras patologías inflamatorias no neoplásicas, las cuales pueden presentar aumento del metabolismo medible. El PET/CT tiene la ventaja de poder detectar enfermedades incluso cuando no tienen un correlato en las imágenes morfológicas, permitiendo además localizar de manera precisa estas alteraciones. Entre estas patologías se encuentran el estudio de fiebre de origen desconocido, enfermedades inflamatorias, enfermedades del tejido conectivo, vasculitis y también en el seguimiento y diagnóstico de algunas patologías infecciosas. Se realizará una revisión en la literatura de la utilidad del PET/CT en estas patologías complementada con casos clínicos.

Biological functions and related diseases of STATs / 中国药科大学学报

@#The signal transducer and activator of transcription(STAT)proteins, which can transmit signals from extracellular to nucleus, play important roles in biological processes. The abnormal activation of STAT3 signaling pathway usually results in many malignant diseases such as tumors(leukemias, lymphomas, breast cancer and lung cancer), inflammation or immune and rheumatoid arthritis. Numerous studies have demonstrated that the activation of STAT3, which means the phosphorylation of the residue 705, can inhibit apoptosis, induce cell proliferation and angiogenesis and finally lead to malignant diseases mentioned above. In this review, the biological functions of STAT family proteins and the related diseases of STAT3 are introduced, and the inhibitors of STAT3 are summarized simply. Further development of STATs is also proposed.

Immunohistochemical Assessment of Peripheral Squamous Lung Cancer: Comparison to Central Squamous Cell Carcinoma and Peripheral Adenocarcinoma

PURPOSE: Incidence of peripheral squamous cell carcinoma (pSCCs) of the lung has increased over recent years, but the immunohistochemical factors involved in pSCCs have not been well established. The aim of this study was to analyze the immunohistochemical differences between pSCCs and central-type SCCs (cSCCs), and similarities between pSCCs and peripheral adenocarcinomas (pADCs). MATERIALS AND METHODS: In this retrospective study, we investigated the expression of three potential prognostic factors (p53, Ki-67, t-CEA), and two potential therapeutic targets (epidermal growth factor receptor [EGFR], and c-erbB-2) in 263 surgically resected cases of primary SCC and pADCs of the lung from January 2001 to July 2008. We divided the SCCs between peripheral and central types, and compared the expression rates of markers between pSCCs and cSCCs, and between pSCCs and pADCs. RESULTS: In this study, there were 149 pADC cases, and among the 114 SCC cases, there were 41 pSCCs (36.0%). There were significantly higher expression rates of Ki-67 and EGFR in pSCCs than in cSCCs or pADCs (p=0.003, p=0.039, respectively). CONCLUSION: We found immunohistochemical differencies in pSCCs from cSCCs and pADCs.